The Stanford Cardiovascular Institute hosted its 2nd Cardiovascular Regenerative Medicine Symposium in May, 2015. Significant advances in our understanding of how to coax cells towards a cardiovascular fate has made it possible to now consider whether these cells are ready for the clinic to repair damaged portions of the heart and vasculature.
We convened leaders in the following areas: biomaterials and scaffolds, cardiac stem cell biology and reprogramming, FDA regulatory policy, clinical trials and the extracellular matrix. Recent progress in these areas called for a conference that encapsulated expertise in both medical and basic research to move forward with regenerative medicine for cardiovascular diseases.
